Diana Sinkevich

VP, Access and Global HEOR at Chiesi Group

Speaker

Currently serving as the Vice President of Market Access EU & International and Global HEOR in the Global Rare Disease Unit of Chiesi Group, Diana Sinkevich oversees market access and value strategies, health technology assessment, and evidence generation across Europe and international markets in various therapeutic areas within the Chiesi rare disease portfolio. Diana is committed to ensuring equal access to specialized care and innovative treatments for all PLWRD, striving to leave no patient behind through robust health economic evidence development despite the methodological limitations inherent in rare disease clinical data packages.

Previously, Diana worked in various life sciences consulting companies, including IQVIA, where she focused on incorporating patients' perspectives into clinical trial design and translating clinical trials and real-world data into a language understandable to all healthcare decision-makers to achieve access for patients living with rare diseases (PLWRD) without delays.

Diana is part of the ISPOR Emerging and Orphan Therapies SIG, exploring fair assessment processes that consider the feasibility of evidence generation and appraisal processes that account for the burden of rare diseases on patients and society when determining value. She is also part of the EFPIA HTA working group which concentrates on EU JCA Regulation.

Diana received a master’s degree in Finance from Bocconi University, Milan, and in Biotechnology from John Hopkins University, Baltimore, as well as a bachelor’s degree in Economics from Bocconi University, Milan. She is currently based in Parma, Italy.